Vertex Pharmaceuticals (VRTX) will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis. That's the assessment from Ian Smith, the company's chief financial officer. The comments were made at the J.P. Morgan Healthcare Conference. There are a few areas that Vertex may explore, including sickle cell disease and Huntington's disease. "We, of course, look at everything in cystic fibrosis," said Smith, in an interview at the conference. "But we also have an interest in diversifying the pipeline beyond cystic fibrosis."
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.